Nilo Therapeutics Secures $101 Million Series A Financing and Appoints New CEO
New york city: Nilo Therapeutics, a biotechnology company focused on leveraging neural circuits to restore immune system balance in diseases, has officially launched with a significant $101 million Series A financing. The funding round was led by The Column Group